Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE GENE THERAPY MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER FIVE ANALYSIS
5 UPDATE ON GERMLINE GENE THERAPY
5.1 GERMLINE GENE THERAPY
6 EUROPE GENE THERAPY MARKET, MO
6.1 DRIVERS
6.1.1 NOVEL APPROACHES TO GENE THERAPY
6.1.2 INCREASING PREVALENCE OF GENETIC DISORDERS
6.1.3 THE GROWING INVESTMENT BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES
6.1.4 GROWING DEMAND FOR PERSONALIZED MEDICINE
6.2 RESTRAINTS
6.2.1 HIGH COST OF GENE THERAPY
6.2.2 ETHICAL AND SAFETY CONCERNS
6.2.3 COMPLEXITY OF GENE THERAPY
6.3 OPPORTUNITIES
6.3.1 RISE IN STRATEGIC ACQUISITION AND PARTNERSHIP AMONG ORGANIZATIONS
6.3.2 RISING APPROVAL FOR GENE THERAPY PRODUCTS
6.4 CHALLENGES
6.4.1 STRINGENT REGULATIONS FOR GENE THERAPY PRODUCTS
6.4.2 LONG-TERM SAFETY AND EFFICACY
7 EUROPE GENE THERAPY MARKET, BY VECTOR TYPE
7.1 OVERVIEW
7.2 VIRAL VECTOR
7.2.1 ADENOVIRUS
7.2.2 RETROVIRUS
7.2.3 LENTIVIRUS
7.2.4 ADENO-ASSOCIATED VIRUS
7.2.5 VACCINIA VIRUS
7.2.6 HERPES SIMPLEX VIRUS
7.2.7 OTHERS
7.3 NON-VIRAL VECTOR
7.3.1 LIPOFECTION
7.3.2 INJECTION OF NAKED DNA
8 EUROPE GENE THERAPY MARKET, BY METHOD
8.1 OVERVIEW
8.2 EX-VIVO
8.3 IN-VIVO
9 EUROPE GENE THERAPY MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 ONCOLOGICAL DISORDERS
9.3 CARDIOVASCULAR DISEASES
9.4 INFECTIOUS DISEASES
9.5 RARE DISEASES
9.6 NUEROLOGICAL DISORDERS
9.7 OTHER DISEASES
10 EUROPE GENE THERAPY MARKET, BY END USER
10.1 OVERVIEW
10.2 CANCER INSTITUTES
10.3 HOSPITALS
10.4 RESEARCH INSTITUTES
10.5 OTHERS
11 EUROPE GENE THERAPY MARKET, BY REGION
11.1 EUROPE
11.1.1 GERMANY
11.1.2 FRANCE
11.1.3 U.K.
11.1.4 ITALY
11.1.5 SPAIN
11.1.6 RUSSIA
11.1.7 TURKEY
11.1.8 NETHERLANDS
11.1.9 BELGIUM
11.1.10 SWITZERLAND
11.1.11 REST OF EUROPE
12 EUROPE GENE THERAPY MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: EUROPE
13 COMPANY PROFILES
13.1 BIOGEN
13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 COMPANY SHARE ANALYSIS
13.1.4 SWOT ANALYSIS
13.1.5 PRODUCT PORTFOLIO
13.1.6 RECENT DEVELOPMENT
13.2 KITE PHARMA
13.2.1 COMPANY SNAPSHOT
13.2.2 REVENUE ANALYSIS
13.2.3 COMPANY SHARE ANALYSIS
13.2.4 SWOT ANALYSIS
13.2.5 PRODUCT PORTFOLIO
13.2.6 RECENT DEVELOPMENT
13.3 NOVARTIS AG
13.3.1 COMPANY SNAPSHOT
13.3.2 REVENUE ANALYSIS
13.3.3 COMPANY SHARE ANALYSIS
13.3.4 SWOT ANALYSIS
13.3.5 PRODUCT PORTFOLIO
13.3.6 RECENT DEVELOPMENTS
13.4 BRISTOL-MYERS SQUIBB COMPANY.
13.4.1 COMPANY SNAPSHOT
13.4.2 REVENUE ANALYSIS
13.4.3 COMPANY SHARE ANALYSIS
13.4.4 SWOT ANALYSIS
13.4.5 PRODUCT PORTFOLIO
13.4.6 RECENT DEVELOPMENT
13.5 OXFORD BIOMEDICA
13.5.1 COMPANY SNAPSHOT
13.5.2 REVENUE ANALYSIS
13.5.3 COMPANY SHARE ANALYSIS
13.5.4 SWOT ANALYSIS
13.5.5 PRODUCT PORTFOLIO
13.5.6 RECENT DEVELOPMENTS
13.6 AGC BIOLOGICS
13.6.1 COMPANY SNAPSHOT
13.6.2 PRODUCT PORTFOLIO
13.6.3 RECENT DEVELOPMENT
13.7 ANGES, INC
13.7.1 COMPANY SNAPSHOT
13.7.2 REVENUE ANALYSIS
13.7.3 PRODUCT PORTFOLIO
13.7.4 RECENT DEVELOPMENT
13.8 AMGEN INC.
13.8.1 COMPANY SNAPSHOT
13.8.2 REVENUE ANALYSIS
13.8.3 PRODUCT PORTFOLIO
13.8.4 RECENT DEVELOPMENT
13.9 BLUEBIRD BIO, INC.
13.9.1 COMPANY SNAPSHOT
13.9.2 PRODUCT PORTFOLIO
13.9.3 RECENT DEVELOPMENT
13.1 CHIESI FARMACEUTICI S.P.A
13.10.1 COMPANY SNAPSHOT
13.10.2 REVENUE ANALYSIS
13.10.3 PRODUCT PORTFOLIO
13.10.4 RECENT DEVELOPMENT
13.11 DENDREON PHARMACEUTICALS LLC
13.11.1 COMPANY SNAPSHOT
13.11.2 PRODUCT PORTFOLIO
13.11.3 RECENT DEVELOPMENT
13.12 ENZYVANT THERAPEUTICS GMBH
13.12.1 COMPANY SNAPSHOT
13.12.2 RODUCT PORTFOLIO
13.12.3 RECENT DEVELOPMENT
13.13 FERRING B.V.
13.13.1 COMPANY SNAPSHOT
13.13.2 PRODUCT PORTFOLIO
13.13.3 RECENT DEVELOPMENT
13.14 JANSSEN PHARMACEUTICALS, INC.
13.14.1 COMPANY SNAPSHOT
13.14.2 PRODUCT PORTFOLIO
13.14.3 RECENT DEVELOPMENT
13.15 MALLINCKRODT.
13.15.1 COMPANY SNAPSHOT
13.15.2 REVENUE ANALYSIS
13.15.3 PRODUCT PORTFOLIO
13.15.4 RECENT DEVELOPMENT
13.16 ORCHARD THERAPEUTICS PLC.
13.16.1 COMPANY SNAPSHOT
13.16.2 REVENUE ANALYSIS
13.16.3 PRODUCT PORTFOLIO
13.16.4 RECENT DEVELOPMENT
13.17 SHANGHAI SUNWAY BIOTECH CO., LTD.
13.17.1 COMPANY SNAPSHOT
13.17.2 PRODUCT PORTFOLIO
13.17.3 RECENT DEVELOPMENT
13.18 SIBONO
13.18.1 COMPANY SNAPSHOT
13.18.2 PRODUCT PORTFOLIO
13.18.3 RECENT DEVELOPMENT
13.19 SPARK THERAPEUTICS, INC.
13.19.1 COMPANY SNAPSHOT
13.19.2 PRODUCT PORTFOLIO
13.19.3 RECENT DEVELOPMENT
13.2 UNIQURE NV.
13.20.1 COMPANY SNAPSHOT
13.20.2 REVENUE ANALYSIS
13.20.3 PRODUCT PORTFOLIO
13.20.4 RECENT DEVELOPMENT
14 QUESTIONNAIRE
15 RELATED REPORTS
List of Table
TABLE 1 EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 2 EUROPE VIRAL VECTOR IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 EUROPE VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 4 EUROPE NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 5 EUROPE NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 6 EUROPE GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)
TABLE 7 EUROPE EX-VIVO IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 8 EUROPE IN –VIVO IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 EUROPE GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 10 EUROPE ONCOLOGICAL DISORDERS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 11 EUROPE CARDIOVASCULAR DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 EUROPE INFECTIOUS DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 EUROPE RARE DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 EUROPE NEUROLOGICAL DISORDERS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 EUROPE OTHER DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 EUROPE GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 17 EUROPE CANCER INSTITUTES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 EUROPE HOSPITALS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 EUROPE RESEARCH INSTITUTES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 EUROPE OTHERS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 EUROPE GENE THERAPY MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 22 EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 23 EUROPE VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 24 EUROPE NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 25 EUROPE GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)
TABLE 26 EUROPE GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 27 EUROPE GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 28 GERMANY GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 29 GERMANY VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 30 GERMANY NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 31 GERMANY GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)
TABLE 32 GERMANY GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 33 GERMANY GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 34 FRANCE GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 35 FRANCE VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 36 FRANCE NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 37 FRANCE GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)
TABLE 38 FRANCE GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 39 FRANCE GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 40 U.K. GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 41 U.K. VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 42 U.K. NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 43 U.K. GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)
TABLE 44 U.K. GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 45 U.K. GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 46 ITALY GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 47 ITALY VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 48 ITALY NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 49 ITALY GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)
TABLE 50 ITALY GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 51 ITALY GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 52 SPAIN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 53 SPAIN VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 54 SPAIN NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 55 SPAIN GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)
TABLE 56 SPAIN GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 57 SPAIN GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 58 RUSSIA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 59 RUSSIA VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 60 RUSSIA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 61 RUSSIA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)
TABLE 62 RUSSIA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 63 RUSSIA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 64 TURKEY GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 65 TURKEY VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 66 TURKEY NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 67 TURKEY GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)
TABLE 68 TURKEY GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 69 TURKEY GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 70 NETHERLANDS GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 71 NETHERLANDS VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 72 NETHERLANDS NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 73 NETHERLANDS GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)
TABLE 74 NETHERLANDS GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 75 NETHERLANDS GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 76 BELGIUM GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 77 BELGIUM VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 78 BELGIUM NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 79 BELGIUM GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)
TABLE 80 BELGIUM GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 81 BELGIUM GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 82 SWITZERLAND GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 83 SWITZERLAND VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 84 SWITZERLAND NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 85 SWITZERLAND GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)
TABLE 86 SWITZERLAND GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 87 SWITZERLAND GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 88 REST OF EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
List of Figure
FIGURE 1 EUROPE GENE THERAPY MARKET: SEGMENTATION
FIGURE 2 EUROPE GENE THERAPY MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE GENE THERAPY MARKET: DROC ANALYSIS
FIGURE 4 EUROPE GENE THERAPY MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE GENE THERAPY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE GENE THERAPY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE GENE THERAPY MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 EUROPE GENE THERAPY MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE GENE THERAPY MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE GENE THERAPY MARKET: SEGMENTATION
FIGURE 11 THE INCREASING PREVALENCE OF GENETIC DISORDERS AND GROWING DEMAND FOR PERSONALIZED MEDICINE ARE EXPECTED TO DRIVE THE GROWTH OF THE EUROPE GENE THERAPY MARKET FROM 2023 TO 2030
FIGURE 12 THE VIRAL VECTOR SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE GENE THERAPY MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE GENE THERAPY MARKET
FIGURE 14 EUROPE GENE THERAPY MARKET: BY VECTOR TYPE, 2022
FIGURE 15 EUROPE GENE THERAPY MARKET: BY VECTOR TYPE, 2023-2030 (USD MILLION)
FIGURE 16 EUROPE GENE THERAPY MARKET: BY VECTOR TYPE, CAGR (2023-2030)
FIGURE 17 EUROPE GENE THERAPY MARKET: BY VECTOR TYPE, LIFELINE CURVE
FIGURE 18 EUROPE GENE THERAPY MARKET: BY METHOD, 2022
FIGURE 19 EUROPE GENE THERAPY MARKET: BY METHOD, 2023-2030 (USD MILLION)
FIGURE 20 EUROPE GENE THERAPY MARKET: BY METHOD, CAGR (2023-2030)
FIGURE 21 EUROPE GENE THERAPY MARKET: BY METHOD, LIFELINE CURVE
FIGURE 22 EUROPE GENE THERAPY MARKET: BY APPLICATION, 2022
FIGURE 23 EUROPE GENE THERAPY MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 24 EUROPE GENE THERAPY MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 25 EUROPE GENE THERAPY MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 26 EUROPE GENE THERAPY MARKET: BY END USER, 2022
FIGURE 27 EUROPE GENE THERAPY MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 28 EUROPE GENE THERAPY MARKET: BY END USER, CAGR (2023-2030)
FIGURE 29 EUROPE GENE THERAPY MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 EUROPE GENE THERAPY MARKET: SNAPSHOT (2022)
FIGURE 31 EUROPE GENE THERAPY MARKET: BY COUNTRY (2022)
FIGURE 32 EUROPE GENE THERAPY MARKET: BY COUNTRY (2023 & 2030)
FIGURE 33 EUROPE GENE THERAPY MARKET: BY COUNTRY (2022 & 2030)
FIGURE 34 EUROPE GENE THERAPY MARKET: VECTOR TYPE (2023-2030)
FIGURE 35 EUROPE GENE THERAPY MARKET: COMPANY SHARE 2022 (%)
